X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
VCN-01 is a systemically administered oncolytic adenovirus designed to selectively and aggressively replicate within tumor cells and degrade the tumor stroma. It is being evaluated in phase 2 clinical trials for the treatment of metastatic pancreatic ductal adenocarcinoma.
Lead Product(s): VCN-01,Paclitaxel,Gemcitabine
Therapeutic Area: Oncology Product Name: VCN-01
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 07, 2024
Details:
VCN-01 is a systemically administered oncolytic adenovirus designed to selectively and aggressively replicate within tumor cells and degrade the tumor stroma that serves as a significant physical and immunosuppressive barrier to cancer treatment.
Lead Product(s): VCN-01,Gemcitabine,Paclitaxel
Therapeutic Area: Oncology Product Name: VCN-01
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 02, 2023
Details:
VCN-01, an intravenous oncolytic adenovirus, designed to replicate selectively and aggressively within tumor cells, and degrade the tumor stroma barrier that serves as a significant physical and immunosuppressive barrier to Pancreatic Cancer treatment.
Lead Product(s): VCN-01,Gemcitabine,Paclitaxel
Therapeutic Area: Oncology Product Name: VCN-01
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 27, 2023
Details:
SYN-004 (ribaxamase) is designed to degrade certain IV beta-lactam antibiotics within the GI tract and maintain the natural balance of the gut microbiome for the prevention of CDI, overgrowth of pathogenic organisms and aGVHD in allogeneic HCT recipients.
Lead Product(s): Ribaxamase,Cefepime
Therapeutic Area: Immunology Product Name: SYN-004
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 16, 2023
Details:
VCN-01, an intravenous oncolytic adenovirus, VCN-01,designed to replicate selectively and aggressively within tumor cells, and to degrade the tumor stroma barrier that serves as a significant physical and immunosuppressive barrier to cancer treatment
Lead Product(s): VCN-01
Therapeutic Area: Oncology Product Name: VCN-01
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 09, 2023
Details:
SYN-004 (ribaxamase), is an oral prophylactic therapy designed to degrade certain IV beta-lactam antibiotics within GI tract, thereby preventing antibiotic-mediated damage to the gut microbiome and reducing adverse outcomes associated with antibiotic-mediated gut dysbiosis.
Lead Product(s): Ribaxamase,Meropenem
Therapeutic Area: Immunology Product Name: SYN-004
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 03, 2022
Details:
VCN-01, an oncolytic adenovirus designed to replicate selectively and aggressively within tumor cells, and to degrade the tumor stroma barrier that serves as a significant physical and immunosuppressive barrier to cancer treatment.
Lead Product(s): VCN-01,Durvalumab
Therapeutic Area: Oncology Product Name: VCN-01
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 24, 2022
Details:
Preclinical results demonstrated that topotecan treatment enhanced VCN-01 oncolytic activity against retinoblastoma. VCN-01, an oncolytic adenovirus expressing hyaluronidase developed by Albumin Shield™ technology.
Lead Product(s): VCN-01,Topotecan Hydrochloride
Therapeutic Area: Oncology Product Name: VCN-01
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 30, 2022
Details:
SYN-004 (ribaxamase) is an oral prophylactic therapy designed to maintain the natural balance of the gut microbiome for the prevention of CDI, overgrowth of pathogenic organisms, the emergence of AMR and aGVHD in allogeneic HCT recipients.
Lead Product(s): Ribaxamase,Cefepime
Therapeutic Area: Immunology Product Name: SYN-004
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 27, 2022
Details:
VCN-01, an oncolytic adenovirus designed to replicate selectively and aggressively within tumor cells, and to degrade the tumor stroma barrier that serves as a significant physical and immunosuppressive barrier to cancer treatment.
Lead Product(s): VCN-01,Durvalumab
Therapeutic Area: Oncology Product Name: VCN-01
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 05, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
